Background: The role of surgery for esophageal squamous cell carcinoma (SCC)with clinical evidence of adjacent organ invasion (cT4) is a debated issue. This study was aimed at analyzing our experience with chemoradiotherapy (CRT) followed by surgery as treatment for non-metastatic cT4 SCC of the thoracic esophagus. Methods: The results of 51 patients consecutively treated at the First Department of General Surgery, University of Verona, from January 1987 to December 2004 were analyzed. Results: The most frequently clinically involved structures were the trachea (43.1%),the main left bronchus (17.6%), and the thoracic aorta (15.7%). CRT was completed in all but one of the patients (98.0%) without toxicity-related deaths. After completion of induction treatment 49 patients underwent surgery (96.1%), and resection was possible in 40 patients (78.4%) but R0 surgery was rarely obtained (39.2%).Pathologic downstaging was achieved in 18 cases (35.3%) while a major response(responders) was observed in 10 patients (19.6%) and a complete response (pT0N0) in7 (13.7%). The overall median survival time was 11.1 months with a 3-year survival rate of 8.8%. A significantly better survival (P < 0.001) was observed after a R0 resection (median: 22.3 months; 3-year survival: 25.4%; P < 0.001) and for responders (median: 33.1 months; 3-year survival: 25.7%; P ¼ 0.019). Conclusions: Aggressive multi-modal therapy with CRT followed by surgery in cT4SCC of the thoracic esophagus is feasible. Surgery should be limited to patients with significant response to induction treatment and a high probability of R0 resection.

Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.

Pedrazzani C;
2007

Abstract

Background: The role of surgery for esophageal squamous cell carcinoma (SCC)with clinical evidence of adjacent organ invasion (cT4) is a debated issue. This study was aimed at analyzing our experience with chemoradiotherapy (CRT) followed by surgery as treatment for non-metastatic cT4 SCC of the thoracic esophagus. Methods: The results of 51 patients consecutively treated at the First Department of General Surgery, University of Verona, from January 1987 to December 2004 were analyzed. Results: The most frequently clinically involved structures were the trachea (43.1%),the main left bronchus (17.6%), and the thoracic aorta (15.7%). CRT was completed in all but one of the patients (98.0%) without toxicity-related deaths. After completion of induction treatment 49 patients underwent surgery (96.1%), and resection was possible in 40 patients (78.4%) but R0 surgery was rarely obtained (39.2%).Pathologic downstaging was achieved in 18 cases (35.3%) while a major response(responders) was observed in 10 patients (19.6%) and a complete response (pT0N0) in7 (13.7%). The overall median survival time was 11.1 months with a 3-year survival rate of 8.8%. A significantly better survival (P < 0.001) was observed after a R0 resection (median: 22.3 months; 3-year survival: 25.4%; P < 0.001) and for responders (median: 33.1 months; 3-year survival: 25.7%; P ¼ 0.019). Conclusions: Aggressive multi-modal therapy with CRT followed by surgery in cT4SCC of the thoracic esophagus is feasible. Surgery should be limited to patients with significant response to induction treatment and a high probability of R0 resection.
squamous cell carcinoma
esophageal cancer
adjacent organ invasion
chemoradiotherapy
surgical treatment
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/737590
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 42
social impact